Global pharma and life sciences deals insights: Q3 2017

Biotech and pharmaceuticals lead M&A activity in Q3

M&A values decreased by over 60% in Q3 2017 as compared to Q2 2017, and the $30.0 billion total deal value was roughly half of the average quarterly value witnessed over the prior two years.  This decrease is driven by declines across all subsectors, except Biotech.  However, the volume of deals was broadly consistent, which demonstrates that underlying demand and activity remains healthy.


Global Pharmaceutical & Life Science Deals Landscape Poised for Growth


Playback of this video is not currently available

Deals activity likely to increase going forward

While some of the challenges in recent quarters may persist, deal activity is likely to increase in the near term. Companies will continue to turn to inorganic methods to supplement growth and innovate their business models. Further, while debt markets may soften, robust deal funding will persist due to strong domestic and international cash balances.

Contact us

Glenn Hunzinger
US Pharmaceutical and Life Sciences Deals Leader
Tel: +1 (646) 471 8764

James Woods
Principal, US Deals
Tel: +1 (617) 530 4133

Follow us